Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

113.13 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,325
Open 113.13
Bid (Size) 113.31 (1)
Ask (Size) 113.51 (1)
Prev. Close 113.13
Today's Range 113.13 - 113.13
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.58%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck Analysts Slash Their Forecasts After Q2 Results
Via Benzinga
Analyzing Merck & Co In Comparison To Competitors In Pharmaceuticals Industry
Via Benzinga

Performance

YTD
-0.10%
-0.10%
1 Month
-11.55%
-11.55%
3 Month
-12.17%
-12.17%
6 Month
-6.33%
-6.33%
1 Year
+7.46%
+7.46%

More News

Read More
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Via InvestorPlace
Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?
Via The Motley Fool
Nasdaq Tumbles Amid Decline In Tech Stocks: Greed Index Moves To 'Fear' Zone
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
Via Benzinga
Topics Economy
Exposures Interest Rates
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Smart Money Is Betting Big In MRK Options
Via Benzinga
Merck (MRK) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Via Benzinga
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Tech Stocks Drop Ahead Of Key Earnings; Nvidia Falls, CrowdStrike Hits 8-Month Low: What's Driving Markets Tuesday?
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
Via Benzinga
Exposures COVID-19
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Via MarketBeat
MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
4 Stocks to Keep High on Your Buy List
Via The Motley Fool
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
Via Benzinga
Exposures Product Safety
Nasdaq, S&P Futures Rise As Microsoft, AMD Earnings Take Spotlight: Will Fed Provide 'Turbo Boost' For Market? Analyst Weighs In
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Merck Posts Stronger-Than-Expected Results, But Outlook Falls Short
Via Investor's Business Daily
Merck Announces Second-Quarter 2024 Financial Results
From Merck & Co., Inc.
Via Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Earnings Divide Dow Industrials As Crux Of Q2 Season Approaches
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
Via Benzinga
Merck Announces Fourth-Quarter 2024 Dividend
From Merck & Co., Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.